BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24616160)

  • 21. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.
    Junge A; Zandi R; Havgaard JH; Gorodkin J; Cowland JB
    Gene; 2017 Jun; 615():35-40. PubMed ID: 28322996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
    Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.
    Tonks A; Pearn L; Musson M; Gilkes A; Mills KI; Burnett AK; Darley RL
    Leukemia; 2007 Dec; 21(12):2495-505. PubMed ID: 17898786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
    Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ
    Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
    Pigazzi M; Manara E; Buldini B; Beqiri V; Bisio V; Tregnago C; Rondelli R; Masetti R; Putti MC; Fagioli F; Rizzari C; Pession A; Locatelli F; Basso G
    Haematologica; 2015 Mar; 100(3):e99-101. PubMed ID: 25480496
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute myeloid leukemia with del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by atypical FISH signals.
    Jang JH; Yoo EH; Kim HJ; Kim DH; Jung CW; Kim SH
    Ann Clin Lab Sci; 2010; 40(1):80-4. PubMed ID: 20124335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RUNX1T1/MTG8/ETO gene expression status in human t(8;21)(q22;q22)-positive acute myeloid leukemia cells.
    Migas AA; Mishkova OA; Ramanouskaya TV; Ilyushonak IM; Aleinikova OV; Grinev VV
    Leuk Res; 2014 Sep; 38(9):1102-10. PubMed ID: 24976338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N
    Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

  • 30. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
    Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
    Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
    Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
    Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
    Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia.
    Flach J; Shumilov E; Joncourt R; Porret N; Tchinda J; Legros M; Scarpelli I; Hewer E; Novak U; Schoumans J; Bacher U; Pabst T
    Genes Chromosomes Cancer; 2020 Apr; 59(4):268-274. PubMed ID: 31756777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Chen D; Chen W
    Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.